Additional file 4: of Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans

a Validation of in vivo flank xenograft experiments using lentiviral ectopic over-expression of candidate genes CCDC115, DNAJC10, RNF149 and STYXL1 in the LNCaP PC cell line. b Flank xenograft tumor growth over time using lentiviral ectopic over-expression of candidate genes RNF149 and STYXL1 in the LNCaP PC cell line. c Flank xenograft final tumor weight after 5Â weeks using lentiviral ectopic over-expression of candidate genes RNF149 and STYXL1 in the LNCaP PC cell line. (PDF 86 kb